Outlook Therapeutics Inc logo

OTLK - Outlook Therapeutics Inc Share Price

$1.26 0.0  3.3%

Last Trade - 19/01/21

Small Cap
Market Cap £114.2m
Enterprise Value £108.4m
Revenue £n/a
Position in Universe 4354th / 6554
Unlock OTLK Revenue
Relative Strength (%)
1m -13.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -29.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Sep 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
5.22 2.98 3.81 3.09 8.15 0.000 0.64 28.6 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 30 September 2020, OutlookTherapeutics Inc revenues decreased from $8.1M to $0K. Netloss applicable to common stockholders increased 36% to$48.9M. Revenues reflect a decrease in demand for theCompany's products and services due to unfavorable marketconditions. Higher net loss reflects Research andDevelopment - Balancing val increase of 31% to $23.7M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


OTLK Revenue Unlock OTLK Revenue

Net Income

OTLK Net Income Unlock OTLK Revenue

Normalised EPS

OTLK Normalised EPS Unlock OTLK Revenue

PE Ratio Range

OTLK PE Ratio Range Unlock OTLK Revenue

Dividend Yield Range

OTLK Dividend Yield Range Unlock OTLK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OTLK EPS Forecasts Unlock OTLK Revenue
Profile Summary

Outlook Therapeutics, Inc., formerly Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab.

Last Annual September 30th, 2020
Last Interim September 30th, 2020
Incorporated October 22, 2015
Public Since June 13, 2016
No. of Shareholders: 111
No. of Employees: 8
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 127,183,109
Free Float (0.0%)
Eligible for
OTLK Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for OTLK
Upcoming Events for OTLK
Friday 12th February, 2021 Estimate
Q1 2021 Outlook Therapeutics Inc Earnings Release
Friday 19th March, 2021 Estimate
Outlook Therapeutics Inc Annual Shareholders Meeting
Thursday 13th May, 2021 Estimate
Q2 2021 Outlook Therapeutics Inc Earnings Release
Frequently Asked Questions for Outlook Therapeutics Inc
What is the Outlook Therapeutics Inc share price?

As of 19/01/21, shares in Outlook Therapeutics Inc are trading at $1.26, giving the company a market capitalisation of £114.2m. This share price information is delayed by 15 minutes.

How has the Outlook Therapeutics Inc share price performed this year?

Shares in Outlook Therapeutics Inc are currently trading at $1.26 and the price has moved by 24.49% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Outlook Therapeutics Inc price has moved by 9.71% over the past year.

What are the analyst and broker recommendations for Outlook Therapeutics Inc?

Of the analysts with advisory recommendations for Outlook Therapeutics Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Outlook Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Outlook Therapeutics Inc next release its financial results?

Outlook Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Outlook Therapeutics Inc dividend yield?

Outlook Therapeutics Inc does not currently pay a dividend.

Does Outlook Therapeutics Inc pay a dividend?

Outlook Therapeutics Inc does not currently pay a dividend.

When does Outlook Therapeutics Inc next pay dividends?

Outlook Therapeutics Inc does not currently pay a dividend.

How do I buy Outlook Therapeutics Inc shares?

To buy shares in Outlook Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Outlook Therapeutics Inc?

Shares in Outlook Therapeutics Inc are currently trading at $1.26, giving the company a market capitalisation of £114.2m.

Where are Outlook Therapeutics Inc shares listed? Where are Outlook Therapeutics Inc shares listed?

Here are the trading details for Outlook Therapeutics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: OTLK
What kind of share is Outlook Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Outlook Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Outlook Therapeutics Inc share price forecast 2021?

Shares in Outlook Therapeutics Inc are currently priced at $1.26. At that level they are trading at 0.28% discount to the analyst consensus target price of 0.00.

Analysts covering Outlook Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.38 for the next financial year.

How can I tell whether the Outlook Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Outlook Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -33.7%. At the current price of $1.26, shares in Outlook Therapeutics Inc are trading at 18.4% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Outlook Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Outlook Therapeutics Inc.

Who are the key directors of Outlook Therapeutics Inc?

Outlook Therapeutics Inc's management team is headed by:

Lawrence Kenyon - PRE
Kurt Hilzinger - IND
Yezan Haddadin - IND
Randy Thurman - CHM
Jeff Evanson - OTH
Terry Dagnon - COO
Gerd Auffarth - DRC
Julian Gangolli - DRC
Andong Huang - DRC
Who are the major shareholders of Outlook Therapeutics Inc?

Here are the top five shareholders of Outlook Therapeutics Inc based on the size of their shareholding:

BioLexis Pte Ltd Corporation
Percentage owned: 42.01% (53.4m shares)
Syntone Ventures LLC Corporation
Percentage owned: 13.23% (16.8m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 1.44% (1.83m shares)
LVW Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 1.37% (1.74m shares)
Sabby Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 1.28% (1.63m shares)
Similar to OTLK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.